已收录 268921 条政策
 政策提纲
  • 暂无提纲
Neurostimulation Treatment of OSA
[摘要] Over the past 30 years, hypoglossal nerve stimulation has moved through a development pathway to become a viable treatment modality for patients with OSA. Initial pilot studies in animals and humans laid the conceptual foundation for this approach, leading to the development of fully implantable stimulating systems for therapeutic purposes. These devices were then shown to be both safe and efficacious in feasibility studies. One such closed-loop stimulating device was found to be effective in treating a limited spectrum of apneic patients and is currently approved by the US Food and Drug Administration for this purpose. Another open-loop stimulating system is currently being rigorously tested in a pivotal trial. Collectively, clinical trials of hypoglossal nerve stimulating systems have yielded important insights that can help optimize therapeutic responses to hypoglossal nerve stimulation. These insights include specific patient selection criteria and methods for delivering stimulation to specific portions of the hypoglossal nerve and/or genioglossus muscle. New approaches for activating efferent and afferent motor pathways are currently in early-stage laboratory development and hold some long-term promise as a novel therapy.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 呼吸医学
[关键词] hypoglossal nerve stimulation;OSA;upper airway stimulation;AHI;apnea-hypopnea index;DISE;drug-induced endoscopy;IPG;implantable pulse generator;Pcrit;critical closing pressure [时效性] 
   浏览次数:8      统一登录查看全文      激活码登录查看全文